Alpine Global Management’s Celldex Therapeutics CLDX Stock Holding History

Alpine Global Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,880	Closed	-$614K	–	493
2021 Q4	$614K	Buy	+15,880	New	+$692K	0.09%	356
2021 Q1	–	Sell	-29,820	Closed	-$522K	–	324
2020 Q4	$522K	Buy	+29,820	New	+$537K	0.11%	99
2014 Q2	–	Sell	-1,667	Closed	-$442K	–	185
2014 Q1	$442K	Buy	+1,667	New	+$638K	0.38%	55

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Alpine Global Management's CLDX Position: Q1 2022 in Review

Alpine Global Management sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 15,880 shares — an estimated $614K sold.

Alpine Global Management first reported a position in CLDX in Q1 2014 and held it in 3 quarters. The position peaked at $614K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

Alpine Global Management reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 15,880 Celldex Therapeutics shares in Q1 2022, an estimated $614K.
Alpine Global Management first reported a position in Celldex Therapeutics in Q1 2014 and held it in 3 quarters.
Alpine Global Management's Celldex Therapeutics position peaked at $614K in Q4 2021.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.